# US 2022/0347243 A1 · Pharmaceutical compositions, kits and methods for treating tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0347243 A1
- Document ID: US20220347243A1
- Status: Published application
- Kind: A1
- Application number: 17/622,217
- Filed: 2019-07-04
- Published: 2022-11-03
- Earliest claimed: 2019-07-04
- Assignees: Immvira Co., Limited
- Applicants: Immvira Co., Limited
- Inventors: Xiaoqing Chen; Xusha Zhou; Bernard Roizman; Grace Guoying Zhou
- Web page: https://patentgrep.com/patent/US20220347243A1

## CPC

- A61K 35/763: Herpes virus
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/208: {IL-12}
- A61P 35/00: Antineoplastic agents
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/54: Interleukins [IL]
- C07K 14/70521: {CD28, CD152}
- C07K 16/2818: {against CD28 or CD152}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/86: Viral vectors
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16633: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2710/16642: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a composition for treating tumors in a subject comprising a therapeutically effective amount of an exosome carrying CTLA4-targeting miRNA and a therapeutically effective amount of an oncolytic herpes simplex virus expressing an immunostimulatory agent or both an immunostimulatory agent and an anti-PD-1 antibody. Wherein an exo-motif operably links to the seed sequence of the CTLA4-targeting miRNA to enhance the packaging of the CTLA4-targeting miRNA into the exosome.

## Claims

### Claim 1

A pharmaceutical composition or a kit for treating a tumor in a subject, comprising,
(a) a therapeutically effective amount of an exosome,
(b) a therapeutically effective amount of an oncolytic herpes simplex virus, and
(c1) a pharmaceutically acceptable carrier, for the pharmaceutical composition, or (c2) optionally instructions for use, for the kit,
wherein the exosome comprises an inhibitory amount of CTLA-4-targeting miRNA and an exo-motif operably linked to a seed sequence of the CTLA-4-targeting miRNA to enhance the packaging of the CTLA-4-targeting miRNA into the exosome, and
wherein the oncolytic herpes simplex virus expresses an immunostimulatory agent or both an immunostimulatory agent and an anti-PD-1 antibody.

### Claim 2 (depends on 1)

The composition or the kit of claim 1, wherein the seed sequence of the CTLA4-targeting miRNA contains any one of the nucleic acid sequences of SEQ ID NO. 1 to SEQ ID NO. 4.

### Claim 3 (depends on 1)

The composition or the kit of claim 1, wherein the exo-motif is selected from a group consisting of nucleic acid sequence of SEQ ID NO. 21 to SEQ ID NO. 49.

### Claim 4 (depends on 1)

The composition or the kit of claim 1, wherein the exo-motif is located downstream and linked to the seed sequence of the CTLA4-targeting miRNA covalently.

### Claim 5 (depends on 1)

The composition or the kit of claim 1, wherein the exo-motif is obtained by mutation of one or more nucleic acids of the CTLA4 targeting miRNA except for the seed sequence.

### Claim 6 (depends on 1)

The composition or the kit of claim 1, wherein the exo-motif is a two-fold motif generated through combination of two single exo-motifs, wherein any of the two single exo-motifs is selected from a group consisting of nucleic acid sequence of SEQ ID NO. 21 to SEQ ID NO. 47.

### Claim 7 (depends on 6)

The composition or the kit of claim 6, wherein the two-fold motif has a nucleic acid sequence of SEQ ID NO. 48.

### Claim 8 (depends on 1)

The composition or the kit of claim 1, wherein CTLA4-targeting miRNA and the exo-motif, when operably linked, share at least one nucleotide or two nucleotides or connect through a linker.

### Claim 9 (depends on 8)

The composition or the kit of claim 8, wherein the linker consists of two or more nucleotides selected from a group consisting of Adenine (A), Guanine (G), Cytosine (C), Thymine (T) and Uracil (U).

### Claim 10 (depends on 9)

The composition or the kit of claim 9, wherein the linker is -GC-.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the CTLA4-targeting miRNA and the exo-motif, when operably linked, has a nucleic acid sequence of SEQ ID NO. 7.

### Claim 12 (depends on 1)

The composition or the kit of claim 1, wherein the immunostimulatory agent is selected from GM-CSF, IL-2, IL-5, IL-12, IL-15, IL-24 and IL-27.

### Claim 13 (depends on 12)

The composition or the kit of claim 12, wherein the immunostimulatory agent is IL-12.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The composition or the kit of claim 1, wherein the oncolytic herpes simplex virus expresses both IL-12 and an anti-PD-1 antibody.

### Claim 16 (depends on 1)

The composition or the kit of claim 1, wherein the oncolytic herpes simplex virus is an HSV-1 expressing IL-12 and anti-PD-1 antibody.

### Claim 17 (depends on 16)

The composition or the kit of claim 16, wherein the HSV-1 is F strain of an HSV-1.

### Claim 18 (depends on 17)

The composition or the kit of claim 17, wherein a fragment of nucleotide sequence from 117005 to 132096 of native backbone is deleted.

### Claim 19 (depends on 1)

The composition or the kit of claim 1, wherein the tumor is a malignant tumor.

### Claim 20 (depends on 19)

The composition or the kit of claim 19, wherein the malignant tumor is selected from a group consisting of melanoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, gastric carcinoma and forestomach carcinoma.

### Claim 21 (depends on 1)

The composition or the kit of claim 1, wherein the subject is human.

### Claim at position 22

22-42. (canceled)

### Claim 43 (depends on 1)

A method for treating a tumor in a subject, comprising administering to the subject the pharmaceutical composition or the kit of claim 1.
